MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Merus NV

Cerrado

SectorSanidad

41.72 -3.27

Resumen

Variación precio

24h

Actual

Mínimo

40.87

Máximo

43.31

Métricas clave

By Trading Economics

Ingresos

69M

-31M

Ventas

-2.6M

9.1M

BPA

-0.49

Margen de beneficios

-338.326

Empleados

260

EBITDA

8.2M

-88M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+107.65% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-119M

3.1B

Apertura anterior

44.99

Cierre anterior

41.72

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Merus NV Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 abr 2025, 23:04 UTC

Principales Noticias

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 abr 2025, 22:40 UTC

Principales Movimientos del Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 abr 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 abr 2025, 18:51 UTC

Adquisiciones, fusiones, absorciones

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 abr 2025, 23:43 UTC

Charlas de Mercado

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 abr 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 abr 2025, 22:22 UTC

Adquisiciones, fusiones, absorciones

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 abr 2025, 22:21 UTC

Adquisiciones, fusiones, absorciones

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 abr 2025, 21:43 UTC

Principales Noticias
Ganancias

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 abr 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

3 abr 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 abr 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 abr 2025, 20:43 UTC

Charlas de Mercado

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 abr 2025, 20:34 UTC

Principales Noticias

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 abr 2025, 20:23 UTC

Principales Noticias

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 abr 2025, 20:15 UTC

Adquisiciones, fusiones, absorciones

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 abr 2025, 19:55 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 abr 2025, 19:55 UTC

Charlas de Mercado

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 abr 2025, 19:21 UTC

Charlas de Mercado

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 abr 2025, 19:15 UTC

Charlas de Mercado

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 abr 2025, 18:45 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 abr 2025, 18:45 UTC

Charlas de Mercado

Gold Drops In Tariff Fallout -- Market Talk

3 abr 2025, 18:39 UTC

Charlas de Mercado

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 abr 2025, 18:38 UTC

Principales Noticias

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 abr 2025, 18:30 UTC

Principales Noticias

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 abr 2025, 18:20 UTC

Charlas de Mercado

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 abr 2025, 18:18 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 abr 2025, 18:17 UTC

Charlas de Mercado

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 abr 2025, 18:04 UTC

Charlas de Mercado

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 abr 2025, 17:55 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Merus NV previsión

Precio Objetivo

By TipRanks

107.65% repunte

Estimación a 12 Meses

Media 89.31 USD  107.65%

Máximo 110 USD

Mínimo 67 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merus NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

15

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

39.31 / 47Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.